following a full submission:
netarsudil plus latanoprost (Roclanda®) is accepted for restricted use within NHSScotland.
Indication under review: for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
SMC restriction: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if:
- the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or
- a fixed-dose combination treatment containing beta-blockers is unsuitable
In a phase III study, netarsudil plus latanoprost was non-inferior to a prostaglandin analogue plus beta-blocker in mean IOP at week 2, week 6 and month 3.
Medicine details
- Medicine name:
- netarsudil / latanoprost (Roclanda)
- SMC ID:
- SMC2720
- Indication:
Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension (OHT) for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
- Pharmaceutical company
- Santen
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 February 2025